Kyntra Bio (FGEN) CEO Thane Wettig awarded 60,000 stock options at $8.50

Rhea-AI Filing Summary

Kyntra Bio, Inc. reported that CEO and director Thane Wettig received a grant of stock options. On February 3, 2026, he was awarded options to purchase 60,000 shares of common stock at an exercise price of $8.50 per share, with no cash price paid for the grant itself.

The options vest in equal amounts quarterly over four years starting from February 3, 2026, and are exercisable until February 2, 2036. Following this award, Wettig beneficially owns 60,000 stock options, held directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Wettig Thane

Role CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	60,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 60,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wettig Thane

(Last) (First) (Middle)

C/O KYNTRA BIO, INC.

350 BAY STREET, SUITE 100, #6009

(Street)

SAN FRANCISCO CA 94133

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KYNTRA BIO, INC. [ KYNB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.5	02/03/2026		A		60,000		(1)	02/02/2036	Common Stock	60,000	$0	60,000	D

Explanation of Responses:

1. The option vests in equal amount quarterly over 4 years measured from 2/3/2026.

	/s/ John Alden, Attorney-in-Fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 filing report for FGEN’s CEO at Kyntra Bio?

The filing reports that CEO and director Thane Wettig received stock options for 60,000 Kyntra Bio common shares at an $8.50 exercise price. These options were granted at no upfront cost and represent a new equity-based compensation award.

How many stock options did Thane Wettig receive according to the Form 4?

Thane Wettig received stock options covering 60,000 shares of Kyntra Bio common stock. These options give him the right to buy those 60,000 shares in the future at a fixed $8.50 per-share exercise price, subject to the vesting schedule.

What is the exercise price and term of Thane Wettig’s Kyntra Bio options?

The options have an exercise price of $8.50 per share and expire on February 2, 2036. This means Wettig can choose to buy Kyntra Bio common shares at $8.50 any time after vesting and before that expiration date, if he wishes.

How do Thane Wettig’s Kyntra Bio options vest over time?

The options vest in equal amounts quarterly over four years, measured from February 3, 2026. Each quarter, a portion of the 60,000 options becomes exercisable, aligning Wettig’s potential benefit with longer-term company performance and service.

How many derivative securities does Thane Wettig own after this transaction?

After the reported grant, Thane Wettig beneficially owns 60,000 stock options related to Kyntra Bio common stock. The Form 4 indicates these options are held directly, reflecting his equity-based interest tied to the company’s future performance.

Was there any cash paid for Thane Wettig’s new Kyntra Bio options?

The options were granted at a price of $0 for the derivative security itself, meaning Wettig did not pay cash to receive them. However, he must pay the $8.50 per-share exercise price if he later chooses to purchase the underlying shares.